On 16 December 2014, orphan designation (EU/3/14/1385) was granted by the European Commission to Immodulon Therapeutics Ltd, United Kingdom, for heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic cancer.
The sponsorship was transferred to Immodulon Therapeutics B.V., Netherlands, in August 2019.
Heat-killed Mycobacterium obuense (whole cell)
|Disease / condition||
Treatment of pancreatic cancer
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.